The Japanese Committee for Clinical Laboratory Standards (JCCLS) has developed a multianalyte conventional reference material (MacRM) for nationwide standardization of laboratory measurements.
. Through these activities, the quality of clinical laboratory test results in Japan has been improved.
Since 1994, a regional effort for standardization of 32 analytes has been ongoing in Fukuoka Prefecture, which has a population of 5 million. This effort has focused on the determination of target values for humanorigin samples at 3 concentrations (low, healthy, and high) that have been used for daily, monthly, and yearly control surveys (3 ) . The standardization of these 32 analytes in Fukuoka Prefecture has been successfully maintained for the past 20 years.
On the basis of the success of the regional standardization in Fukuoka, JCCLS has worked since 2005 to extend the program to nationwide standardization, using human sera with target values traceable to certified reference materials as a multianalyte conventional reference material (MacRM). The use of human sera was the critical point for the nationwide standardization project, because human sera has no matrix effect when measured with any of the commercial assay kits available in Japan.
The standardization program has fundamentally contributed to the Measures for National Health Promotion by the Ministry of Health, Labour, and Welfare in Japan, including its 21st Century Measures for National Health Promotion and New Goals of Health Japan 21, for "reducing the number of patients and those that have a high risk of contracting metabolic syndrome (visceral fat syndrome)" (4 ) .
This article describes the development of MacRM, using human sera with target values assigned for 30 analytes, and its successful application to nationwide standardization in Japan.
Materials and Methods

PREPARATION OF POOLED HUMAN SERA
We obtained sera of approximately 18 000 healthy Japanese donors (16 -69 years old, male-to-female ratio 6:4) from the Japanese Red Cross Blood Center in accordance with Ministry of Health, Labour, and Welfare guidelines (5 ) . Pooled sera were prepared as previously described (3 ) .
In brief, approximately 2 mL serum was obtained from 400 -500 individual donors and pooled at 4°C to yield approximately 800 mL pooled serum that was frozen at Ϫ80°C. This process was repeated to yield a total of 32-35 L frozen pooled sera in approximately 800-mL aliquots.
To prepare a batch of pooled serum, the aliquots of frozen pooled sera were thawed by flowing tap water at 20°C-25°C over a period of 2 h. The thawed aliquots were filtered with a membrane plasma separator (PF-50N, pore size 400 nm, Nipro Pharma Corp.) to remove aggregations and chylomicrons. After filtration, the pool was pumped through a hollow fiber dialyzer LC, pore size 6 nm, Nipro Pharma Corp.) to adjust the concentration of albumin (Alb) from 4.0 to 5.0 g/dL.
We modulated the concentrations of analytes by adding high-quality reagents: glucose, uric acid, urea nitrogen, creatinine (Cre), iron, sodium, potassium, chloride, calcium, inorganic phosphate, magnesium, JCCLS-CRM001 [aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CK), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), ␥-glutamyl transferase (GGT), and amylase], and JCCLS-CRM002 (cholinesterase). The specifications for pooled sera are shown in Supplementary Table 1, which accompanies the online version of this article at http:// www.clinchem.org/content/vol62/issue2 and lists the desired ranges for the low and high concentrations of 30 analytes.
The total volume of the processed pooled sera was 20 -30 L. The serum pool was dispensed 2 mL each into a 5.0-mL vacuum blood collecting tube (Nipro Pharma Corp.). The tubes were frozen and stored at Ϫ80°C and delivered to participating laboratories packed on dry ice with temperature monitors that confirmed receipt in the frozen state. The pooled sera were confirmed to be uncontaminated by chyle, hemolysis, C-reactive protein (CRP) (Ͻ0.005 g/L), hepatitis B antigen, hepatitis C virus antibody, Treponema pallidum, or HIV.
Target values for 30 analytes were assigned to the pooled sera by 45 JAMT-certified laboratories (for MacRM-000) and 18 JAMT-certified laboratories (for MacRM-001). Among these laboratories, 14 (MacRM-000) and 10 (MacRM-001) had International Organization for Standardization (ISO) 15189 accreditation by the Japan Accreditation Board, and the rest of the laboratories had a demonstrated level of quality that was equivalent to ISO15189 accreditation. The 45 JAMTcertified laboratories demonstrated calibration traceability to the certified reference materials (CRMs) listed in Table 1 . Consequently, the values assigned to the processed sera used as secondary reference materials were traceable to these CRMs. Target values for total protein (TP) and total bilirubin (TB) were assigned by use of the mean values determined by the 45 JAMT-certified laboratories, because there was no available reference material for these analytes in Japan. The processed pooled sera with target values for 30 analytes was defined as MacRM. Two lots of MacRM (MacRM-000 and MacRM-001) were prepared for use as calibrators in this study.
To survey laboratories for assessment of the success of standardization, we prepared processed pooled sera having 2 concentrations (sample 1 and sample 2) essentially by the same procedure used for MacRM preparation but without value assignment.
All measurements (except for the case of commutability assessment) made by the laboratories involved in this study (the 45 JAMT-certified and 165 general labo- ratories) were performed with quintuplicate automated analyses.
COMMUTABILITY ASSESSMENT OF MacRM
We performed the commutability assessment with residual sera from 150 inpatients in Fukuoka University Chikushi Hospital after routine laboratory testing was completed. Aliquots (approximately 1-2 mL each) of individual sera stored at 4°C for a day were periodically collected from the same patient until the total volume collected from 1 patient was 10 mL. During the collection period, each serum was frozen at Ϫ80°C, and additional sera were added to the frozen material as it became available. The 10 mL frozen sera was thawed over a period of 10 min by flowing tap water at 20°C-25°C, centrifuged to remove aggregates, divided into 0.5-mL aliquots, and refrozen at Ϫ80°C for a few days up to 1 year until use. Sera from patients were grouped into 5 categories on the basis of having relatively high values for various combinations of analytes. Group 1 had increased glucose, uric acid, urea nitrogen, Cre, inorganic phosphate, and Fe. Group 2 had increased Na, K, Cl, Ca, Mg, and CRP. Group 3 had increased AST, ALT, ALP, LDH, amylase, CK, GGT, and TB. Group 4 had increased total cholesterol, triglycerides, HDL cholesterol (HDL-C), and LDL-C. Group 5 had increased TP, Alb, IgG, IgA, IgM, and cholinesterase. Each group consisted of 30 patients' sera, and each set for commutability assessment consisted of 5 groups.
One set of sera for commutability assessment and 2 lots of MacRM (000 and 001), 2 mL each, for use as a calibrator were sent frozen on dry ice to 28 laboratories with temperature monitors that confirmed receipt in the frozen state. In the individual laboratories, the patient sera and MacRM were measured according to their own routine methods including duplicate automated analyses. Online Supplementary Table 2 shows the assay methods of each analyte and the laboratories' market shares in Japan. All combinations of assay kits and platforms used in Japan were examined for the commutability assessment.
CALCULATIONS OF INTRAINSTITUTION VARIATIONS, INTERINSTITUTION ALLOWABLE ERROR LIMITS, AND UNCERTAINTIES
The allowable error limits for individual measurements and the goals for interinstitution differences were determined according to previous research (6 -10 ) . The allowable error limits for the intrainstitution variation (CV A ) were calculated as Ͻ0.50CV I , and the goals for interinstitutional differences (B A ) (allowable bias) were calculated as Ͻ0.25(CV I 2 ϩ CV G 2 ) 0.5 , where CV I is intraindividual variation and CV G is interindividual variation.
The CV A , B A , CV I , and CV G for the 30 analytes in Japan were previously published (3, 11 ) .
The uncertainty components consist of the relative standard uncertainty related to characterization and the uncertainties due to between-bottle heterogeneity, possible degradation during long-term storage, and uncertainty of a certified value of the reference material (12) (13) (14) (15) . The relative expanded uncertainty was calculated from the relative combined standard uncertainty by multiplication with a coverage factor k, taken as 2, corresponding to a level of confidence of approximately 95%. The allowable limits of error for assessment of trueness were calculated as the square root of the sum of squares of the uncertainty of the assigned value and the SD of between-laboratory variation of the reference measurement procedures.
STATISTICAL ANALYSES
Statistical analysis was carried out on the basis of the procedures outlined by ISO standards (12) (13) (14) (15) .
Results and Discussion
EVALUATION OF THE 45 JAMT-CERTIFIED LABORATORIES WITH CRMs AND TARGET VALUES OF MacRM
The accuracy of all measurements of the 45 JAMTcertified laboratories was evaluated by assaying CRMs. Table 1 shows the origins and target values of CRMs and the measured values of CRMs determined by the 45 JAMT-certified laboratories. The targets and measured values were quite consistent with each other for 28 analytes. The values for bias and CV were reasonably small and within the goals for interinstitutional differences (B A ) except for electrolytes (Na, Cl, Ca) and albumin. Because the allowable bias (B A ) for Na, Cl, and Ca was very small, it was difficult to achieve standardization within the B A goals with the present analytical technology. The CVs for Na, Cl, and Ca were 0.6%, 1.0%-1.3%, and 1.5%-1.7%, respectively, all of which were close to the allowable error limits, and the CV of Alb (1.9%) was also close to the allowable error limit of 1.6%. These results indicate that the 45 JAMT-certified laboratories were qualified to determine target values for the MacRM and that the target values for the MacRM determined by the 45 JAMT-certified laboratories were traceable to the values assigned to the CRMs for the 28 analytes.
The target values of 2 other analytes (TP and TB) were assigned using the mean values of the MacRM measured by the 45 JAMT-certified laboratories. The quality of the 45 JAMT-certified laboratories has been maintained by periodically assaying CRMs. Table 2 and online Supplementary Table 3 show the target values and uncertainties of MacRM-000 and MacRM-001, established by the 45 JAMT-certified laboratories and the 18 JAMT-certified laboratories, respectively. Raw data for determination of uncertainties of MacRM-001 are summarized in online Supplementary Table 4 .
STABILITY OF MacRM AT −80°C FROZEN STATE FOR 4 YEARS
The practical stability of MacRM was examined after storage at Ϫ80°C in 165 individual general laboratories located in 47 prefectures throughout Japan. These 165 general laboratories used the MacRM as calibrator for the 30 analytes in 2011 and monitored changes for the 30 analytes over 2011 to 2014. During this period, an aliquot of frozen MacRM was thawed once a year, and the 30 analytes were measured in quintuplicate with each laboratory's routine automated measurement procedures. Table 2 shows the target values of MacRM-000 and the values measured in each of the 4 years by 165 general laboratories. The mean values of the 30 analytes were consistent with their individual target values, and all had bias Ͻ3.0%. Therefore, we concluded that MacRM-000 was stable in the Ϫ80°C frozen state for at least 4 years.
ASSESSMENT OF MacRM COMMUTABILITY
As described in Materials and Methods, we performed a commutability assessment using residual sera from 150 inpatients after routine laboratory testing was completed. Two lots of MacRM (000 and 001), 2 mL each, for use as a calibrator and 1 set of sera for commutability assessment (0.5 mL each of 150 sera) were sent to 28 laboratories with temperature monitors that confirmed receipt in the frozen state. With these patients' sera, we examined the relationships between patient sera, 2 lots of MacRM (000 and 001), and the CRMs used for traceability of the MacRM target values for all combinations of assay methods and assay platforms (shown in online Supplementary  Tables 2, 4 , and 5) of the 30 analytes in 28 laboratories. Fig. 1 shows the matched-pair analyses on the analyte of LDL-C as a typical case. Values of MacRM-001 and CRMs were noted to fall on the regression lines of patients' samples, meaning that for LDL-C, MacRM-001 was commutable.
For the remaining 29 analytes, except Fe and Alb, the twin-plot analyses demonstrated close agreement between results for patient samples and MacRM-001, as shown in online Supplementary Figs. 1-30 . These results indicate that the MacRM-001 was commutable for all combinations of assay methods and assay platforms used for the 30 analytes except Fe and Alb. When the Fe and Alb assays were calibrated with MacRM-001, the relative residual was large, at approximately 10% between the Ortho dry-chemistry assay and the Fujifilm drychemistry assay compared with the Hitachi Nitroso-PSAP assay (for example, see online Supplementary Figs. 6 and 26). When assays were calibrated with Institute for Reference Materials and Measurements European Reference Material Da470k, an approximate 10% residual was noted between the bromocresol green (BCG) and bromocresol purple (BCP) methods (for example, see online Supplementary Fig. 26a, b) .
Generally, however, the MacRM was a useful conventional reference material for standardizing the 30 analytes in Japan and provided traceability to the values assigned to the CRMs. Raw data of patient samples are summarized in online Supplementary Table 5 .
Virtually identical results to those found with MacRM-001 were obtained with the other lot of MacRM-000 (see online Supplementary Figs. 31-60) .
A MODEL STUDY OF NATIONWIDE STANDARDIZATION USING 2 SURVEY SAMPLES WITH LOW AND HIGH CONCENTRATIONS
JCCLS performed a model study by having 165 general laboratories located in 47 prefectures throughout Japan calibrate their routine assays with the MacRM materials. Survey samples having 2 concentrations (sample 1 and sample 2) were assayed by all 165 laboratories during 15 weeks per year from 2011 to 2013. Table 3 shows the allowable biases (B A ) for 29 analytes and the means, SDs, and CVs for the 30 analytes for the surveys over 3 years. The CVs of 25 of 30 analytes were within the allowable biases (B A ) for both sample 1 and sample 2. The CVs for Na, Cl, and Ca were close to the allowable values. For the Mg analysis, we did not have an allowable bias, but the CV for Mg measurements was Ͻ4.5%. Although the CV of Alb was twice as much as its allowable bias (B A ), the CV was Ͻ3.5%.
The number of laboratories that met the allowable error limits for the intrainstitution variation from 2011 to 2013 is shown in online Supplementary Table 6 . The percentages of laboratories among 165 general laboratories that met the allowable error limits (CV A ) were Ͻ90% for the analytes Cre, TB, Alb, IgG, IgA, and IgM. For 21 of 30 analytes, however, Ͼ90% of the general laboratories met the individual allowable error limits.
The survey samples used to assess the success of standardization were processed pools made with the same method as the MacRM, so there is a possibility that any matrix-related biases would be the same and thus not detected. However, this limitation is unlikely, because the MacRM was commutable for all combinations of assay methods and assay platforms used for the 30 analytes (for example, see Fig. 1 and online Supplementary  Figs. 1-60) .
Thus, we confirmed that standardization was achieved for 30 analytes used for primary medical care in 165 general laboratories throughout Japan when MacRM was used as a calibrator for correcting interassay bias once a year using quintuplicate automated analyses, although various assay kits and platforms were used in these 165 general laboratories (for example, see online  Supplementary Tables 2, 4 MacRM-001 (2 mL each) for use as a calibrator and 1 set of sera for commutability assessment [0.5 mL each of 150 sera (30 patients' sera in 5 groups)] were sent to 28 laboratories with temperature monitors that confirmed receipt in the frozen state. In the individual laboratories, the patient sera and MacRM-001 were measured according to their own routine methods including duplicate automated analyses. With these patients' sera, we examined the relationships between patient sera (•), MacRM-001 (Ⅺ), and the CRMs (‚) used for traceability of the MacRM target values for all combinations of assay methods and assay platforms (shown in online Supplemental Tables 2, 4 Table 1 . All measurements taken by the laboratories were performed according to their own routine methods using quintuplicate automated analysis.
